{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:11:24Z","timestamp":1770815484900,"version":"3.50.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rift Valley fever virus (RVFV) is one of the most important virulent pathogens causing severe disease in animals and humans. However, there is currently no approved vaccine to prevent RVFV infection in humans. The use of human adenovirus serotype 4 (Ad4) as a vector for an RVFV vaccine has not been reported. Here, we report the generation of a replication-competent recombinant Ad4 vector expressing codon-optimized forms of the RVFV glycoproteins Gn and Gc (named Ad4-GnGc). Intramuscular immunization with Ad4-GnGc elicited robust neutralizing antibodies against RVFV and cellular immune responses in mice. A single low-dose vaccination with Ad4-GnGc completely protected interferon-\u03b1\/\u03b2 receptor-deficient A129 mice from lethal RVFV infection. More importantly, Ad4-GnGc efficacy was not affected by pre-existing immunity to adenovirus serotype 5, which currently exists widely in populations. These results suggest that Ad4-GnGc is a promising vaccine candidate against RVFV.<\/jats:p>","DOI":"10.3389\/fimmu.2022.907675","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:13:09Z","timestamp":1668143589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Single-dose of a replication-competent adenovirus-vectored vaccine provides sterilizing protection against Rift Valley fever virus challenge"],"prefix":"10.3389","volume":"13","author":[{"given":"Ting","family":"Bian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Busen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangcheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or rift valley fever. an undescribed virus disease of sheep cattle and man from East Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J Pathol Bacteriol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(01)24634-0","article-title":"Rift valley fever","volume":"219","author":"Daubney","year":"1932","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.008","article-title":"Present and future arboviral threats","volume":"85","author":"Weaver","year":"2010","journal-title":"Antivir Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0376-y","article-title":"Past and future spread of the arbovirus vectors aedes aegypti and aedes albopictus","volume":"4","author":"Kraemer","year":"2019","journal-title":"Nat Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/mve.12254","article-title":"Rift valley fever virus and European mosquitoes: Vector competence of culex pipiens and stegomyia albopicta (= aedes albopictus)","volume":"31","author":"Brustolin","year":"2017","journal-title":"Med Vet Entomol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.01.004","article-title":"Rift valley fever","volume":"37","author":"Hartman","year":"2017","journal-title":"Clin Lab Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of rift valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1086\/378747","article-title":"Rift valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(02)00295-9","article-title":"Rift valley fever: An uninvited zoonosis in the Arabian peninsula","volume":"21","author":"Balkhy","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1038\/emi.2016.136","article-title":"The first imported case of rift valley fever in China reveals a genetic reassortment of different viral lineages","volume":"6","author":"Liu","year":"2017","journal-title":"Emerg Microbes Infect"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3201\/eid1712.111035","article-title":"Molecular epidemiology of rift valley fever virus","volume":"17","author":"Grobbelaar","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines5030029","article-title":"Current status of rift valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated smithburn rift valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J Med Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PloS Negl Trop Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(99)00218-2","article-title":"Immunogenicity of an inactivated rift valley fever vaccine in humans: A 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored rift valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of Chadox1 rvf vaccine against rift valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41426-018-0102-5","article-title":"An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques","volume":"7","author":"Feng","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.Cov2.S vaccine for covid-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: A placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored covid-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-Human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.07.033","article-title":"Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits","volume":"34","author":"Choudhry","year":"2016","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030411","article-title":"Live oral adenovirus type 4 and type 7 vaccine induces durable antibody response","volume":"8","author":"Collins","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau2710","article-title":"Prolonged evolution of the memory b cell response induced by a replicating adenovirus-influenza H5 vaccine","volume":"4","author":"Matsuda","year":"2019","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.6.2933-2940.2006","article-title":"Rescue of infectious rift valley fever virus entirely from cdna, analysis of virus lacking the nss gene, and expression of a foreign gene","volume":"80","author":"Ikegami","year":"2006","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against sars-Cov-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal rift valley fever virus (Rvfv) infection in transgenic ifnar(-\/-) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001421","article-title":"Tissue tropism and target cells of nss-deleted rift valley fever virus in live immunodeficient mice","volume":"5","author":"Gommet","year":"2011","journal-title":"PloS Negl Trop Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41541-020-00218-y","article-title":"A protective bivalent vaccine against rift valley fever and bluetongue","volume":"5","author":"Calvo-Pinilla","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","article-title":"A novel highly sensitive, rapid and safe rift valley fever virus neutralization test","volume":"248","author":"Schreur","year":"2017","journal-title":"J Virol Methods"},{"key":"B34","doi-asserted-by":"publisher","first-page":":685\u2013712","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The global phosphorylation landscape of sars-Cov-2 infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell [Internet]"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00936-07","article-title":"Highly sensitive and broadly reactive quantitative reverse transcription-pcr assay for high-throughput detection of rift valley fever virus","volume":"45","author":"Bird","year":"2007","journal-title":"J Clin Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250329","article-title":"Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing Igg2a, Igg2b and Igg3 antibody subclasses in vivo","volume":"25","author":"Germann","year":"1995","journal-title":"Eur J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00531-8","article-title":"Interferon-armed rbd dimer enhances the immunogenicity of rbd for sterilizing immunity against sars-Cov-2","volume":"31","author":"Sun","year":"2021","journal-title":"Cell Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"14917","DOI":"10.1038\/s41598-021-94364-5","article-title":"Intranasal plus subcutaneous prime vaccination with a dual antigen covid-19 vaccine elicits T-cell and antibody responses in mice","volume":"11","author":"Rice","year":"2021","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.12.024","article-title":"Induction of Th1 and Th2 in the protection against sars-Cov-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein","volume":"40","author":"Chung","year":"2022","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific Cd8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002309","article-title":"A single immunization with mva expressing gngc glycoproteins promotes epitope-specific Cd8+-T cell activation and protects immune-competent mice against a lethal rvfv infection","volume":"7","author":"Lopez-Gil","year":"2013","journal-title":"PloS Negl Trop Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","article-title":"Germinal-center organization and cellular dynamics","volume":"27","author":"Allen","year":"2007","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular helper cell biology: A decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy187","article-title":"Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models","volume":"218","author":"Guo","year":"2018","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/BF01309641","article-title":"The synergistic neutralization of rift valley fever virus by monoclonal antibodies to the envelope glycoproteins","volume":"125","author":"Besselaar","year":"1992","journal-title":"Arch Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-018-0052-x","article-title":"A rift valley fever virus gn ectodomain-based DNA vaccine induces a partial protection not improved by apc targeting","volume":"3","author":"Chrun","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against rift valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of Chadox1 ncov-19 vaccine administered in a prime-boost regimen in young and old adults (Cov002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and mva-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5n1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored covid-19 vaccine confers protection from sars-Cov-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein nss","volume":"75","author":"Bouloy","year":"2001","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.907675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:13:13Z","timestamp":1668143593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.907675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2022.907675"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.907675","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"article-number":"907675"}}